Clinical trials: Hepatic Malignancies
Colorectal Cancer, Cholangiocarcinoma
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
This study is being done to answer the following question: Is the combination of the Medtronic pump and the Codman catheter device a safe alternative to the C3000 Codman pump for delivering chemotherapy directly into the liver of…
- Trial name
- NCT03693807
- Testing
- Medtronic pump and Codman catheter, Floxuridine (FUDR), Gemcitabine
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer, Liver Metastases
ALPPS Versus PVE/PL
Study Title Comparison of two different models of liver growth stimulation in advanced colorectal liver metastatic disease, (LIGRO Trial) enabling liver resection Methodology Scandinavian Multiple Center Randomized Registry Based…
- Trial name
- LIGRO (NCT02215577)
- Testing
- In-situ split, Portal embolization or ligation
- Where
- 7 sites in Denmark, Norway and 1 more
- Volunteers
- 100 people
- Sponsor
- Regionalt Cancercentrum Väst
Hepatocellular Carcinoma, Liver Cancer
HR Versus RFA for Early Stage HCC
Hepatocellular carcinoma (HCC) is the third leading death cancer in the world. It is important to explore a safe and effective therapy for early-stage HCC.
- Trial name
- ARTC-HCC (NCT02169765)
- Testing
- Hepatic resection, Radiofrequency ablation
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangxi Medical University
Hepatic Carcinoma
Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function
The purpose of this study is to investigate the safety and efficacy of irreversible electroporation for unresectable Hepatic carcinoma in poor liver function, also Progress Free Survival (PFS) and Over Survival (OS) will be…
- Trial name
- NCT02352935
- Testing
- NanoKnife LEDC System
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Hepatocellular Carcinoma
Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria
The purpose of this study is to evaluate the efficacy and safety of resection plus neoadjuvant hepatic arterial infusion chemotherapy (HAIC) compared with resection alone in patients with resectable hepatocellular carcinoma…
- Trial name
- NCT03469479
- Testing
- FOLFOX, Hepatic resection
- Where
- 7 sites in China
- Volunteers
- 252 people
- Sponsor
- Sun Yat-sen University
Liver Function Failure, Liver Malignant Tumors
Assessment of Remnant Liver Function in ALPPS by Gd-EOB-DTPA Enhanced MRI
Insufficient future liver remnant (FLR), which may render post-hepatectomy liver failure, is one of the major obstacles for performing liver resection for patients with liver malignants.
- Trial name
- NCT04559451
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Third Hospital
Hepatocellular Carcinoma
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
The study is being conducted to evaluate the efficacy and safety of conversion treatment of Hepatic Arterial Infusion Chemotherapy combined with Camrelizumab and Apatinib for unresected hepatocellular carcinoma.
- Trial name
- NCT05099848
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shandong Cancer Hospital and Institute
Cholangiocarcinoma
Regorafenib Versus Placebo to Treat Cholangiocarcinoma
The study is a multicenter randomized (1:1) placebo-controlled, double-blinded phase II trial aiming to demonstrate an improvement of median PFS when treating locally advanced unresectable or metastatic patients suffering from an…
- Trial name
- REACHIN (NCT02162914)
- Testing
- Regorafenib/active
- Where
- 12 sites in Belgium
- Volunteers
- 66 people
- Sponsor
- Erasme University Hospital
Hepatocellular Carcinoma
Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After HAIC for Locally Advanced HCC
Prospective single arm, single center observational study to evaluate factors which were easily available from preoperative examination for predicting therapeutic effects and clinical prognosis of hepatic artery infusion…
- Trial name
- NCT05002452
- Testing
- Search of factors predicting therapeutic effects and prognosis
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
Clinical Application of Quantitative Major Imaging Features of CEUS LI-RADS
Liver cancer (LC) is the sixth most common malignant tumor and the third cause of cancer mortality in the world. According to the 2018 United States Association for the Study of Liver Diseases guidelines for the diagnosis and…
- Trial name
- NCT06590948
- Testing
- contrast-enhanced ultrasound
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Recurrent Liver Cancer After Liver Transplantation
Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation
For patients with recurrent liver cancer after liver transplantation, the median survival time is low and the prognosis is often poor.
- Trial name
- NCT05833126
- Testing
- Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shuhong Yi
Cancer, COPD
SELF-BREATHE RCT for Chronic Breathlessness
A feasibility RCT comprising two groups: 1. Intervention (SELF-BREATHE in addition to standard NHS care) 2. Control group (standard / currently available NHS care)
- Conditions
- Cancer, COPD, Asthma, Bronchiectasis Adult
- Trial name
- NCT04574050
- Testing
- SELF-BREATHE
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- King's College Hospital NHS Trust
Primary or Metastatic Hepatic Adenocarcinoma
Cardiac Output Optimization on Postoperative Complications in Major Hepatic Surgery
Major hepatectomies are high-risk surgeries offered more and more frequently for the curative treatment of primary or secondary liver cancer, and for complex cases, representing a real challenge for medical teams.
- Trial name
- OPTILIVER (NCT04655885)
- Testing
- Optimization of cardiac flow by base water-electrolyte supply, Control arm
- Where
- France
- Volunteers
- 186 people
- Sponsor
- Institut Paoli-Calmettes
Hepatic Carcinoma, Hepatic Metastasis
Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.
The goal of this double-blind clinical trial is to compare the efficacy of octreotide versus placebo in laparoscopic hepatectomy surgery in patients diagnosed with resectable hepatocarcinoma or liver metastases.
- Trial name
- NCT06085976
- Testing
- Octreotide
- Where
- Spain
- Volunteers
- 62 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Neoplasms, Liver
A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma
The primary purpose of this study is to determine the maximum tolerable dose (MTD) and/or the maximum feasible dose (MFD), as well as to evaluate the safety of JX-594 (Pexa-Vec) injected within hepatic carcinoma tumors.
- Trial name
- NCT00629759
- Testing
- JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Jennerex Biotherapeutics
Adhesion, Liver Neoplasms
The Efficacy of a Topical Anti-adhesive Film for Decreasing Perihepatic Adhesions in Repeat Hepatic Surgery
There has been an increase in the need for repeat hepatic surgery, especially for patients with colorectal liver metastasis and hepatocellular carcinoma.
- Trial name
- NCT04641923
- Testing
- Adhesion barrier
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Calgary
Intrahepatic Cholangiocarcinoma (Icc)
PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma
The goal of this trial is to determine whether the combination of CISGEM and Rilvegostomig during the perioperative period works to improve outcomes of patient undergoing surgery of high-risk of intrahepatic cholangiocarcinoma
- Trial name
- PEHRICCA (NCT07128290)
- Testing
- CISGEM + Rilvegostomig
- Where
- 9 sites in France
- Volunteers
- 49 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Cholangiocarcinoma Non-resectable
Preoperative Right Hepatic Artery Embolization for Locally Advanced Bismuth IIIb and IV Perihilar Cholangiocarcinoma
This is a prospective, multicenter, single-arm study investigating the efficacy and safety of preoperative right hepatic artery embolization (PHAE) followed by surgical resection in patients with locally advanced Bismuth IIIb or…
- Trial name
- PHAE-PHCC (NCT07326189)
- Testing
- Preoperative Right Hepatic Artery Embolization
- Volunteers
- 33 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Liver Cancer
Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures
This study was designed to confirm that the surgeon is able to perform surface registration of standard liver features used as landmarks during a scheduled laparoscopic liver procedure.
- Trial name
- NCT01237990
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Pathfinder Therapeutics
Metastatic Colorectal Cancer
Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases
Bevacizumab, an anti-angiogenic agent, plus fluorouracil based chemotherapy is considered a new standard for the treatment of metastatic colorectal cancer.
- Trial name
- NCT00489697
- Testing
- real-time contrast-enhanced ultrasound imaging (CEUS)
- Where
- 12 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Tours